American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share
- Symbol
- ZLAB
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
ZAI LAB LTD
ZAILFOTCEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 5, 2026, Zai Lab Limited issued a press release announcing its financial results for the third quarter of 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.…
Press release in this filing
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates →Company context
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.
Current securities
Registered securities in this filing
ZAI LAB LIMITED · 8-K · Filed 2026-11-05
Ordinary Shares, par value $0.000006 per share*
- Symbol
- 9688
- Exchange
- Not supplied
- Classification
- COMMON
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, Zai Lab Limited issued a press release announcing its financial results for the third quarter of 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
The information contained in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates Zai Lab anticipates major catalysts in 2027 across multiple global programs with transformative potential: - Zoci 1.6 mg/kg plus atezolizumab showed compelling 1L SCLC data at ESMO: 81.8% confirmed ORR, an estimated 81.9% six-month PFS rate and 9.1% Grade ≥3 zoci-related AEs; advancing toward a global Phase 3 study in 1L SCLC - Registrational global Phase 3 DLLEVATE study evaluating zoci in 2L+ SCLC is ongoing, with a potential interim analysis in the second half of 2027, followed by a subsequent U.S. accelerated approval submission - Completed enrollment in zoci’s potentially registrational 2L epNECs expansion cohort, with data expected in the first half of 2027, followed by a subsequent U.S. accelerated approval submission - ZL-1503, a long-acting IL-13/IL-31Rα bispecific antibody, is advancing toward key clinical milestones including initial first-in-human data at 2026 ACAAI and atopic dermatitis patient data expected in the first half of 2027 - Total revenues of $108.2 million in the third quarter of 2026 with 2% sequential net product revenue growth; positioned for a return…
Open exhibit ↗